Santhosh Ambika
@RenoHemonc
Oncologist/Hematologist- Doing my part to help onc patients. + fintwit
Prophylactic itacitinib (200 mg) twice daily was effective in preventing CRS and ICANS in patients who underwent CD19-directed IEC therapy. ow.ly/3wzs50WuY43
Neoadjuvant PD-1/PD-L1 blockade combined with chemotherapy improved pathological response rates and surgical resectability in patients with T4 and/or N2-N3 stage III NSCLC. ja.ma/4kXyeAx @EdoardoGarbo
BREAKING: "The Justice Department is investigating whether the renowned NewYork-Presbyterian health system violated antitrust laws through hidden deals with insurance companies that kept hospital prices high" Reported by @nytimes @JoeKGoldstein nytimes.com/2025/07/28/nyr…
PREOPANC2 is a great ex of ignoring data that doesn't fit one's priors. Many (myself included) were surprised by results, but it's a Ph3 RCT & data are the data. Gem-based RT is cheaper, less toxic than FFX; future trials should consider building off this regimen as baseline.
This is a great read. D-FLOT approved for all gastric/GEJ adeno (at least in US), but which subset of patients appear to benefit most? Plus, importance of considering MATTERHORN in context of multiple other negative IO trials. Look forward to more of this on your Substack!
Do check out my post on Substack 🙂👇 about matterhorn Trial open.substack.com/pub/dramolakha… @brunolarvol @oncodaily @Timothee_MD @dr_yakupergun @OncBrothers
“Stark doesn’t prevent abuse. It created a whole cottage industry of compliance consultants and lawyers who profit off the complexity while physicians are told to sit tight, follow shifting safe harbors, and be grateful we’re allowed to own anything at all.”
Every time I post about Stark on LinkedIn, I get 50 consultants in my replies telling me I’m doing it wrong. That I don’t understand the law. That Stark “protects patients.” That physicians can still own things—if we pay them to help us navigate the maze. That’s the point. Stark…
Characterization of adenosquamous NSCLC and carcinosarcoma from @TheShieldsLab now @JTOonline. Actionable alterations (including METex14, EGFR, KRAS G12C, ALK, RET) seen in 37% of adenosquamous and in 17% of carcinosarcoma samples. jto.org/article/S1556-…
🚨 New data from the POETIC study in ER+/HER2+ early #BreastCancer thelancet.com/journals/ebiom… ▪️2 weeks of AI → 79% Luminal B ➡️ Luminal A ✅Those shifting had 5x ↓ relapse risk (HR 0.2) 🎯 Luminal A → ET alone may be enough ⛔ If still B → consider CDK4/6i Looks like POETIC…
🚨 New therapy approved in #sarcoma! @EMA_News has granted the use of 🎯CSFR1 #vimseltinib in patients with #TGCT with funtion deterioration and in whom surgical options have been exhausted or would induce unacceptable morbidity or disability ▶️ema.europa.eu/en/medicines/h…
Phase I results of obrixtamig (DLL3-CD3 bispecific T-cell engager) @JCO_ASCO (n=168 SCLC / neuroendocrine carcinoma). Across doses/cohorts, RR 23%, DOR 8.5m (in large cell neuroendocrine, RR 70%). CRS in 57% (G3+ 3%). Active challenger to tarlatamab. ascopubs.org/doi/10.1200/JC…
Wish that this trial had included a fulvestrant/everolimus arm, rather than randomizing 131 patients to fulvestrant monotherapy.
Results from VIKTORIA-1 just announced by @celcuity. The addition of gedatolisib to 2L fulvestrant/palbo improved PFS from 2 to 9.3 months (HR 0.24). Also the fulvestrant/gedatolisib combo improved PFS vs fulv mono (7.4 vs 2 mo, HR 0.33). Quite promising. morningstar.com/news/globe-new…
Results from VIKTORIA-1 just announced by @celcuity. The addition of gedatolisib to 2L fulvestrant/palbo improved PFS from 2 to 9.3 months (HR 0.24). Also the fulvestrant/gedatolisib combo improved PFS vs fulv mono (7.4 vs 2 mo, HR 0.33). Quite promising. morningstar.com/news/globe-new…
$CELC PFS curves for the triplet & doublet PIK3CA-wt cohorts
phase 2 study of Mosun-Pola in high risk R/R MCL (71% pts, all had BTKi, with 3+ high risk factors), yet all responded equally with ORR 88% and CR 78%. A 5 year perseverance and team work
Hear as @elizabeth_budde of @cityofhope shares the promising results of a Phase II study evaluating mosunetuzumab plus polatuzumab vedotin in pts with R/R #MantleCellLymphoma & high-risk features. Click here: 🎥 ow.ly/Qbm450WtM2c #LYMsm #18ICML #CTSM #TrialUpdate…
🧵THE GREAT AMERICAN HEALTHCARE TAX DODGE How “nonprofit” health systems perfected grift without any legal consequences. Monopolies. No taxes. Charity cosplay. Here’s how they broke the system and made you pay for it.
The hospitals are responsible for spiraling healthcare costs. That bill has some high prices listed for physician services, imaging, and medications. But the money isn’t making it to the doctors or even the pharma companies. Those are all markups being pocketed by the hospital.…
American “Just got my first hospital bill after my first time ever staying in the hospital. This is extortion. This is why everyone hates our medical system” He says he had high blood pressure, was in the ER less than 2 hours, no surgery, No CAT scan, no MRI, this was his bill…
Talquetamab demonstrated efficacy in patients previously exposed to T-cell redirecting therapies, with response rates comparable to treatment-naive patients. hubs.li/Q03y-cSf0 #mmsm | @bhemato | @CMHBolivar
FDA’s cancer review teams have lost about 1/3 of the medical review staff that oversee products for breast and gynecological cancers and the malignant heme group may lose about 2/3 of its medical review staff—all to voluntary resignations clustered among more seasoned reviewers
1/ BREAKING: The Medicaid-insurer model is collapsing in real time. Centene: down 61% Molina: down 55% Humana: lost $300/share UnitedHealth: down 46% YTD and under federal investigation This isn’t just a sell-off. It’s the end of the myth. 🧵 Let’s go.
📋Key trials in intermediate stage HCC #ESMOGI25 @myESMO @OncoAlert @realbowtiedoc #cancer #oncology #MedX #HCC